Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $35.70

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $35.70.

Several brokerages have recently commented on VRDN. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Royal Bank of Canada lifted their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. Finally, TD Cowen started coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating on the stock.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $15.46 on Thursday. The firm has a market capitalization of $1.26 billion, a PE ratio of -3.59 and a beta of 1.05. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $11.40 and a 12-month high of $27.20. The firm has a 50-day moving average price of $16.98 and a 200 day moving average price of $19.77.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The business had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Research analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the business. R Squared Ltd acquired a new stake in Viridian Therapeutics during the 4th quarter worth $26,000. Foresite Capital Management VI LLC acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth $38,000. AlphaQuest LLC increased its holdings in Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after purchasing an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after buying an additional 1,516 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Viridian Therapeutics during the third quarter worth about $149,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.